Committee for Advanced Therapies - Strategic Review and Learning Meeting

The Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) is responsible for the scientific guidance of the pre-authorisation phase of the medicine as well as the assessment of the quality, safety and efficacy of advanced therapy medicinal products (ATMP) during the authorisation process and post-authorisation. During the SRLM, the Committee discuss issues regarding its activities and determines its future strategic planning.